Latest Breaking News On - Victor levitsky - Page 1 : comparemela.com

Circio debuts proof-of-concept for circVec gene therapy at ASGCT 2024

Circio debuts proof-of-concept for circVec gene therapy at ASGCT 2024
biopharma-reporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharma-reporter.com Daily Mail and Mail on Sunday newspapers.

United statesVictor levitskyThomas hansen

Circio : Annual Report 2023 Report - MarketScreener

Annual Report 2023 25 April 2024 Annual Report.

United statesBruxelles capitaleGeorgetown universityDistrict of columbiaThomasb hansenThomas hansenBristol myers squibbVictor levitskyErik digman wiklundErikd wiklundFredrik schjesvoldEuropean society of geneCircio groupChinese national medical products administrationEuropean patent officeNorwegian research council

Targovax to present at upcoming conferences

/PRNewswire/ Targovax ASA today announces that members of its executive management team are invited to present and participate in upcoming conferences..

United kingdomPrnewswire targovax asatodayOystein sougVictor levitskyAndreas tinglumRenate birkeliErik digman wiklundGen immunoCorporate communications norwayLife science investorLone ottesen

Targovax to present at the 4th Annual Next Gen Immuno-oncology Virtual Congress-US Edition

Share this article OSLO, Norway, June 28, 2021 /PRNewswire/ Targovax ASA, today announces that Victor Levitsky, Chief Scientific Officer of Targovax, is invited to present at the 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition. 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition, virtual Date: 29 June 2021

Oystein sougPrnewswire targovaxVictor levitskyAndreas tinglumGen immunoRenate birkeliKim sutton golodetzCorporate communications norwayChief scientific officerAnnual next gen immuno oncology virtualSutton golodetzவெற்றியாளர் லெவிட்ஸ்கிகேன் இம்யூனோபெருநிறுவன தகவல்தொடர்புகள் நோர்வேதலைமை அறிவியல் அதிகாரி

Reminder: Invitation to Targovax s Capital Markets Day 18 February 2021

Share this article OSLO, Feb. 18, 2021 /PRNewswire/ Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital Markets Day for investors, analysts and journalists today at 2:30 PM CET. The Capital Markets Day will feature presentations from executive management and Alexander Shousthari, Clinical Director Melanoma Services at Memorial Sloan Kettering Cancer Center, and will be webcast live and accessible at https://www.targovax.com/en/capital-markets-day-2021/ Based on the strong clinical data that are now generated on ONCOS-102, Targovax has a solid fundament to move into late stage clinical development. We also have a broader pipeline of preclinical assets that could create a broader horizon of opportunities in the future. The Capital Markets day will feature presentations updating the market on these aspects.

Alexander shousthariVictor levitskyAlexander shoushtariisAndreas tinglumAlexandern shoushtariPrnewswire targovaxRenate birkeliKim sutton golodetzCorporate communications norwayMelanoma servicesMemorial sloan kettering cancer centerCapital markets dayClinical director melanoma servicesCapital marketsClinical directorMemorial sloan kettering cancer